Suzhou, November 20, 2023/PRNewswire/ -- On November 20, 2023, Suzhou Boteng Biopharmaceutical Co., Ltd. (hereinafter referred to as Boteng Biotech) announced that it has reached a strategic cooperation with Ascoli (Suzhou) Biotechnology Co., Ltd. (hereinafter referred to as Ascoli) to jointly promote the development and production of NK cells, help development and innovation in the field of gene and cell therapy, and accelerate the application of NK cells in the field of cancer prevention, beauty and anti-aging.

Boteng Biotech is committed to providing end-to-end gene and cell therapy CDMO services, covering fields such as plasmids, cell therapy, gene therapy, oncolytic viruses, nucleic acid therapy, and live bacterial therapy. At present, it has successfully helped customers complete CMC and global application services for various gene and cell therapy drugs. Ascoli focuses on the development and production of breakthrough immune cell therapy products, mainly focusing on the field of NK/CAR-NK anti-tumor immune cell therapy drugs, and has built a complete immune cell therapy R&D and production system, with three major technology platforms: general CAR-NK, allogeneic NK/Car-NK, and mRNA-LNP. According to the agreement, Boteng Biotech will provide development and production and China application services for the Ascoli NK Cell Project to support its application in the fields of cancer prevention, anti-aging, and beauty.

Dr. Li Huashun, founder and chairman of Ascoli, said, “CAR-NK cell therapy has potential in fighting cancer. This treatment uses genetic engineering to modify NK cells so that they can better identify and kill tumor cells while reducing damage to normal cells. In the field of treatment of solid tumors, CAR-NK cell therapy has advantages. Furthermore, in terms of anti-aging of NK cells, a single dose of 2 billion young healthy cells can reduce circulating senescent cells by up to 80%-100%^[1] , and the continuous efficiency is over 3 months to 18 months. Ascle-NK has deep accumulation and process advantages in the NK field. We have created the Ascle-NK platform to cultivate superior NK cells. At the same time, Boteng Biotech has made impressive achievements in the research and development, production, and project application of gene and cell therapeutics. I believe that with its rich experience and expertise, Boteng Biotech can provide important support for Ascot's promotion of the application of NK cells in anti-aging, beauty, and cancer prevention.”

Dr. Wang Yangzhou, CEO of Boteng Biotech, said, “We are very pleased to have reached a strategic partnership with Ascoli. Ascoli's R&D pipeline has deep accumulation and advantages, especially in the NK field. Boteng Biotech has established an end-to-end CDMO platform for gene and cell therapy. It has excellent process development capabilities and an aseptic drug production workshop. The production capacity and experience of high-quality GMP cell products can be customized according to customer needs. At the same time, Boteng Biotech also has advanced international analytical method development technology and platforms to ensure the quality and safety of future products, and is empowered to support Asco's R&D and production projects with international production inspection and release standards. We are very much looking forward to close cooperation and strong integration with Asco Power to jointly promote the CMC and China application of the NK Cell project. Through Boteng Biotech's CDMO platform, we are quickly helping Asco achieve new progress in the field of NK cell anti-aging, cosmetic, and cancer prevention.”